Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression

Prostaglandins and Other Lipid Mediators

Volumn 93, Issue 3-4, 2010, Pages 100-108

  Koontongkaew, Sittichai ^a,b   Monthanapisut, Paopanga ^a   Saensuk, Theeranuch ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Aspirin; Cell invasion; Colon cancer; COX; ETYA; Head and neck cancer; LOX; MMPs; NDGA; NS 398; NSAIDs; Sulindac

Indexed keywords

5,8,11,14 ICOSATETRAYNOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; NORDIHYDROGUAIARETIC ACID; SULINDAC;

ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LIPOXYGENASE; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 78149414375     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.07.002     Document Type: Article

References (46)

1. Ondrey F.G. Arachidonic acid metabolism: a primer for head and neck surgeons. Head Neck 1998, 20:334-349.
2. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992, 89:7384-7388.
3. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-33160.
4. Dannenberg A.J., Altorki N.K., Boyle J.O., Lin D.T., Subbaramaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci 2001, 952:109-115.
5. Mestre J.R., Chan G., Zhang F., et al. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci 1999, 889:62-71.
6. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
7. Gallo O., Franchi A., Magnelli L., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3:53-61.
8. Klapan I., Katic V., Culo F., Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J Cancer Res Clin Oncol 1992, 118:308-313.
9. Culo F., Klapan I., Katic V., Kolak T., Bakula B. Production of prostaglandin E by squamous carcinoma of the head and neck and adenocarcinoma of gastrointestinal tissue. Med Oncol Tumor Pharmacother 1992, 9:35-39.
10. Camacho M., Leon X., Fernandez-Figueras M.T., Quer M., Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 2008, 30:1175-1181.
11. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989, 259:315-324.
12. Steele V.E., Holmes C.A., Hawk E.T., et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999, 8:467-483.
13. Shureiqi I., Lippman S.M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001, 61:6307-6312.
14. Ondrey F.G., Juhn S.K., Adams G.L. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996, 106:129-134.
15. Li N., Sood S., Wang S., et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005, 11:2089-2096.
16. Rosenthal E.L., Matrisian L.M. Matrix metalloproteases in head and neck cancer. Head Neck 2006, 28:639-648.
17. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215:1-20.
18. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24:96-102.
19. Lin D.T., Subbaramaiah K., Shah J.P., Dannenberg A.J., Boyle J.O. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002, 24:792-799.
20. Altorki N.K., Subbaramaiah K., Dannenberg A.J. COX-2 inhibition in upper aerodigestive tract tumors. Semin Oncol 2004, 31:30-36.
21. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
22. Sinicrope F.A., Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004, 23:63-75.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
24. Smith M.L., Hawcroft G., Hull M.A. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000, 36:664-674.
25. Koontongkaew S., Amornphimoltham P., Yapong B. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells. Cell Biol Int 2009, 33:165-173.
26. Albini A., Iwamoto Y., Kleinman H.K., et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47:3239-3245.
27. Hanif R., Pittas A., Feng Y., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52:237-245.
28. Sheng H., Shao J., Kirkland S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997, 99:2254-2259.
29. Yang C.Y., Meng C.L., Liao C.L., Wong P.Y. Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat 2003, 72:115-130.
30. Galfi P., Neogrady Z., Amberger A., Margreiter R., Csordas A. Sensitization of colon cancer cell lines to butyrate-mediated proliferation inhibition by combined application of indomethacin and nordihydroguaiaretic acid. Cancer Detect Prev 2005, 29:276-285.
31. Sumitani K., Kamijo R., Toyoshima T., et al. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 2001, 30:41-47.
32. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002, 531:278-284.
33. Sood S., Shiff S.J., Yang C.S., Chen X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol 2005, 41:562-567.
34. Meng C.L., Yang C.Y., Shen K.L., Wong P.Y., Lee H.K. Inhibition of the synthesis of eicosanoid-like substances in a human oral cancer cell line by interferon-gamma and eicosapentaenoic acid. Arch Oral Biol 1998, 43:979-986.
35. Minter H.A., Eveson J.W., Huntley S., Elder D.J., Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003, 9:1885-1897.
36. Tong W.G., Ding X.Z., Adrian T.E. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002, 296:942-948.
37. Larkins T.L., Nowell M., Singh S., Sanford G.L. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006, 6:181.
38. Attiga F.A., Fernandez P.M., Weeraratna A.T., Manyak M.J., Patierno S.R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000, 60:4629-4637.
39. Kinugasa Y., Hatori M., Ito H., Kurihara Y., Ito D., Nagumo M. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 2004, 21:737-745.
40. Jiang M.C., Liao C.F., Lee P.H. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 2001, 282:671-677.
41. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-3340.
42. Takaoka K., Kishimoto H., Segawa E., et al. Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol 2006, 29:1095-1101.
43. Ishizaki T., Katsumata K., Tsuchida A., et al. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 2006, 17:357-362.
44. Karna E., Palka J.A. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol 2002, 443:1-6.
45. Dohadwala M., Batra R.K., Luo J., et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002, 277:50828-50833.
46. Miyamoto H., Altuwaijri S., Cai Y., Messing E.M., Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 2005, 44:1-10.